Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07860775 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.

Study acronym: HOVON 180 CLL
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The Haemato Oncology Foundation for Adults in the Netherlands (HOVON) has designed this study. Researchers (all doctors) are conducting the study at various hospitals in the Netherlands, Denmark and Sweden. The study medicines pirtobrutinib and epcoritamab that are used in this study are made available by pharmaceutical companies Eli Lilly and AbbVie. This study is also funded by AbbVie and Eli Lilly. HOVON needs 70 participants for this study. The purpose of this study is to find out how safe and effective the combination of pirtobrutinib tablets and subcutaneous epcoritamab is for patients with CLL whose disease has come back after previous treatment or whose disease did not respond well to the previous treatment. The goal is to suppress the CLL to such an extent that the disease does not come back for a long time.
Trial Details
NCT Number NCT07860775
Lead Sponsor Stichting Hemato-Oncologie voor Volwassenen Nederland
Conditions CLL / SLL
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov